Testing its role in cancer immunotherapy, Ohno et al.19 showed that a lack of IL-6 produced in a tumor-bearing host augments induction of anti-tumor effector T-cells and inhibits tumorigenesis in vivo. Here, IL6 is linked to neoplasm.